scholarly journals Response assessment classification in patients with advanced renal cell carcinoma treated on clinical trials

Cancer ◽  
2003 ◽  
Vol 98 (8) ◽  
pp. 1611-1619 ◽  
Author(s):  
Lawrence H. Schwartz ◽  
Madhu Mazumdar ◽  
Liang Wang ◽  
Alex Smith ◽  
Stephanie Marion ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Clinical Trials ◽  
Cell Carcinoma ◽  
Renal Cell ◽  
Response Assessment ◽  
Advanced Renal Cell Carcinoma

scholarly journals The role of PD-L1 expression as a predictive biomarker in advanced renal cell carcinoma: A meta-analysis of randomized clinical trials

2019 ◽  
Vol 30 ◽  
pp. v40
Author(s):  
A. Carretero-Gonzalez ◽  
I. Martín Sobrino ◽  
I. Sáez Sanz ◽  
D. Castellano Gauna ◽  
G.A. De Velasco Oria de Rueda
Keyword(s):  
Renal Cell Carcinoma ◽  
Clinical Trials ◽  
Cell Carcinoma ◽  
Renal Cell ◽  
Randomized Clinical Trials ◽  
Meta Analysis ◽  
Predictive Biomarker ◽  
Advanced Renal Cell Carcinoma

scholarly journals Overall Survival Endpoint in Oncology Clinical Trials: Addressing the Effect of Crossover - The Case of Pazopanib in Advanced Renal Cell Carcinoma

Oncology ◽  
2016 ◽  
Vol 90 (3) ◽  
pp. 119-126 ◽  
Author(s):  
Jose Diaz ◽  
Cora N. Sternberg ◽  
Faisal Mehmud ◽  
Thomas E. Delea ◽  
Nicholas Latimer ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Overall Survival ◽  
Clinical Trials ◽  
Cell Carcinoma ◽  
Renal Cell ◽  
Advanced Renal Cell Carcinoma ◽  
Oncology Clinical Trials ◽  
Survival Endpoint

Tolerability of axitinib in advanced renal cell carcinoma: A meta-analysis.

2021 ◽  
Vol 39 (15_suppl) ◽  
pp. e16536-e16536
Author(s):  
Bareia Chaudhry ◽  
Shenhong Wu
Keyword(s):  
Renal Cell Carcinoma ◽  
Clinical Trials ◽  
Adverse Events ◽  
Cell Carcinoma ◽  
Renal Cell ◽  
Fixed Effects ◽  
Meta Analysis ◽  
Single Agent ◽  
Advanced Renal Cell Carcinoma ◽  
Discontinuation Rate

e16536 Background: Axitinib has been used extensively as a single agent or in combination with immunotherapy in the treatment of advanced renal cell carcinoma. It can be often discontinued due to adverse events. A meta-analysis of clinical trials was performed to evaluate the overall tolerability of axitinib in this setting. Methods: PubMed (Up to November 2020) was searched to identify clinical trials of axitinib in advanced or metastatic renal cell carcinoma. Reported data was collected to include axitinib and control discontinuation due to adverse events. A random or fixed effects model was used to determine summary incidences, relative risks, and 95% confidence intervals depending on the heterogeneity of included studies. Results: A total of 11 studies including 4,056 patients (axitinib alone n = 1384, axitinib combination n = 987, control n = 1685) were included for analysis. The summary discontinuation rate for axitinib due to adverse events was 13.4% (95% CI; 11.7-15.2%) with 8.9% (95% CI: 5.3-14.6%) as a single agent and 26.6% (95% CI:17.8 –37.8%) in combination with other agents. In comparison with controls based on randomized controlled studies, axitinib overall has similar discontinuation rate due to adverse events (RR: 1.18, 95% CI: 0.77-1.80). However, there was a significantly higher discontinuation rate with axitinib in combination with other agents including immunotherapeutic agents PD-L1 inhibitors than control treatment (RR: 1.52, 95% CI: 1.24-1.86). Conclusions: The tolerability of axitinib may vary significantly with its use as a single agent or in combination in the treatment of advanced renal cell carcinoma. Further studies are needed to improve its tolerability as a part of combination therapy.

Sign in / Sign up

Export Citation Format

Share Document